Some antibody medicines, including Ronapreve, may not be effective against the highly mutated omicron variant of the coronavirus, according to researchers at Japanese and U.S. institutes.
The findings by Yoshihiro Kawaoka, a professor of virology at the University of Tokyo's Institute of Medical Science, and others were published in the New England Journal of Medicine on Wednesday.
The researchers examined the neutralizing ability of approved and investigational therapeutic antibodies against omicron and other variants of concern.